Talecris Biotherapeutics


RESEARCH TRIANGLE PARK, North Carolina, November 15, 2010 - Talecris Biotherapeutics announced today the publication of combined data from two studies demonstrating that augmentation therapy with Alpha(1) -Proteinase Inhibitor (Human) (A1PI) significantly reduces lung tissue loss in patients with emphysema related to Alpha(1)-antitrypsin (AAT) deficiency.

BARCELONA, Spain, September 20, 2010 - Talecris Biotherapeutics GmbH announced yesterday the recipients of the 2010 European alpha1-antitrypsin Laurell's Training Awards (eALTA).
Older News
S M T W T F S
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
Copyright© 2010 The Gaea Times